Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Free Report)’s share price fell 1.3% during trading on Wednesday . The stock traded as low as $0.40 and last traded at $0.41. 45,408 shares traded hands during trading, a decline of 93% from the average session volume of 697,094 shares. The stock had previously closed at $0.41.
Altamira Therapeutics Price Performance
The stock’s fifty day moving average is $0.47 and its two-hundred day moving average is $0.83.
Altamira Therapeutics Company Profile
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
Featured Stories
- Five stocks we like better than Altamira Therapeutics
- Health Care Stocks Explained: Why You Might Want to Invest
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- 3 Warren Buffett Stocks to Buy Now
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-corinth-refineries-sa-logo-1200x675.png&h=45&w=95&zc=2){kind=logo}
